Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Cited by (330)

Items 101–200 of 330

1. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: a systematic review and meta-analysis
   Reyes-Farias, Carlos Ignacio, Reategui-Diaz, Marcelo, Romani-Romani, Franco, Prokop, Larry · 2023 · PLOS ONE
2. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis
   Yaling Bai, Jingjing Jin, Wei Zhou, Shenglei Zhang, Jinsheng Xu · 2021 · Nutrition Metabolism and Cardiovascular Diseases
3. Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases
   Sebastian Steven, Marin Kuntić, Thomas F. Münzel, Andreas Daiber · 2025 · Pharmacological Reviews
4. The effects of home-based progressive resistance training in chronic kidney disease patients
   Thaís Branquinho de Araújo, Hugo de Luca Corrêa, Lysleine Alves Deus, Rodrigo Vanerson Passos Neves, Andrea Lucena Reis, Fernando Sousa Honorato, Jessica Mycaelle da Silva Barbosa, Thalyta Railine Cesar Palmeira, Samuel da Silva Aguiar, Caio Victor Sousa et al. · 2022 · Experimental Gerontology
5. Updates in heart failure
   Oliver Rees, P Wheen, Lisa J Anderson · 2023 · Clinical Medicine
6. Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
   Wanying Geng, Wanying Liao, Xinyuan Cao, Yingyun Yang · 2025 · Biomedicines
7. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials
   Gong Chen, Shichun Shen, Ke Zhang, Lei Zhou, Junjie Shen, Jiaying Zhao, Sheng-Gang Ding, Likun Ma, Hui Gao · 2022 · Frontiers in Cardiovascular Medicine
8. Series: Implications of the recent CVOTs in type 2 diabetes
   André Jacques Scheen · 2019 · Diabetes Research and Clinical Practice
9. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study
   for the DARWIN-T2D Network, Gian Paolo Fadini, Patrizia Li Volsi, Eleonora Devangelio, M. Poli, Giuliana Cazzetta, Giuseppe Felace, Angelo Avogaro · 2019 · Journal of Endocrinological Investigation
10. The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
    Jiang Liu, Jiang Tian, Komal Sodhi, Joseph I. Shapiro · 2021 · The Journal of Membrane Biology
11. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
    André Jacques Scheen · 2020 · Clinical Pharmacokinetics
12. Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors
    Serge A Jabbour, Nasrien E. Ibrahim, Christos Argyropoulos · 2022 · Journal of Clinical Medicine
13. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes
    Marcello Casaccia Bertoluci, Wellington Santana da Silva Júnior, Fernando Valente, Levimar Rocha Araujo, Ruy Lyra, João Jácome de Castro, João Filipe Raposo, Paulo Augusto Carvalho Miranda, César Luiz Boguszewski, Alexandre Hohl et al. · 2023 · Diabetology & Metabolic Syndrome
14. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
    Leonardo Pozo, Fatimah Oluwakemi Bello, Andrés Suárez, Francisco E. Ochoa-Martinez, Yamely H. Mendez, Chelsea Chang, Salim Surani · 2019 · World Journal of Diabetes
15. SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials
    Hai‐Bin Chen, Yao‐Lin Yang, Tian-Hao Yu, Yuhui Li · 2022 · European Journal of Pharmacology
16. Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients
    Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama · 2023 · Metabolites
17. Evaluation of the Effect of Sodium-Glucose Cotransporter 2 Inhibition on Fracture Risk: Evidence From Mendelian Randomization and Genetic Association Study
    Huajie Dai, Longyi Zheng, Zheng Zhu, Xin Geng, Tianzhichao Hou, Qi Wang, Yijie Zhu, Hong Lin, Shuangyuan Wang, Ruizhi Zheng et al. · 2023 · Journal of Bone and Mineral Research
18. The impact of weight loss on renal function in individuals with obesity and type 2 diabetes: a comprehensive review
    Xuemei Gong, Xiaoxi Zeng, Ping Fu · 2024 · Frontiers in Endocrinology
19. Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors
    Fan Yang, Ran Meng, Dalong Zhu · 2020 · Chronic Diseases and Translational Medicine
20. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Renal Transplant Patients With Diabetes: A Brief Review of the Current Literature
    Shirley Shuster, Zeyana Al-Hadhrami, Sarah Moore, Sara Awad, M. Khaled Shamseddin · 2021 · Canadian Journal of Diabetes
21. Diabetes Mellitus and Diabetic Kidney Disease: The Future Is Already Here
    Alberto Martínez‐Castelao · 2023 · Journal of Clinical Medicine
22. Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
    Jiahua Li, Christopher O Fagbote, Min Zhuo, Chelsea E. Hawley, Julie M. Paik · 2019 · Clinical Kidney Journal
23. SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery
    Giovanna B. Carpentieri, Sandra Elisa Adami Batista Gonçalves, Mayra Zanon Casagrande, Walid M. Mourad, Lara Guimarães Carelo Pinto, Maria Teresa Zanella · 2022 · Obesity Surgery
24. NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR DIABETES MELLITUS, HEART FAILURE AND KIDNEY DISEASE
    Mariana Cornelia Tilinca · 2023 · FARMACIA
25. Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation
    Ying‐Ju Lai, Yung‐Hsin Yeh, Yen‐Lin Huang, Celina De Almeida, Gwo‐Jyh Chang, Wei-Jan Chen, Hsao‐Hsun Hsu · 2024 · ACS Pharmacology & Translational Science
26. Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia
    Takashi Wada, Akinori Hara, Eri Muso, Shoichi Maruyama, Sawako Kato, Kengo Furuichi, Kenichi Yoshimura, Tadashi Toyama, Norihiko Sakai, Hiroyuki Suzuki et al. · 2020 · Clinical and Experimental Nephrology
27. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
    Brian Tomlinson, Paul Chan, Christopher Wai Kei Lam · 2021 · Expert Opinion on Pharmacotherapy
28. Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?
    Sohail Aziz, Siti Maisharah Sheikh Ghadzi, Syed Azhar Syed Sulaiman, Nur Hafzan Md Hanafiah, Sabariah Noor Harun · 2021 · Journal of Pharmacy And Bioallied Sciences
29. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity
    Reza Golchin Vafa, Amirreza Sabahizadeh, Ramina Mofarrah · 2023 · Current Problems in Cardiology
30. Investigating the research trajectory and future trends of immune disorders in diabetes cardiovascular complications: A bibliometric analysis over the past decade based on big data
    Xinglei Li, Xu Zhou, Tieqiu Huang, Yixin Jiang, Huan Wan, Deju Zhang, Jitao Ling, Yuting Wu, Xiao Liu, Pingping Yang et al. · 2024 · Ageing Research Reviews
31. Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor
    Kazuo Shimizu, Hideki Fujikura, Nobuhiko Fushimi, Toshihiro Nishimura, Kazuya Tatani, Kenji Katsuno, Yoshikazu Fujimori, Shinjiro Watanabe, Masahiro Hiratochi, Takeshi Nakabayashi et al. · 2021 · Bioorganic & Medicinal Chemistry
32. A comprehensive review on the antidiabetic attributes of thiazolidine‐4‐ones: Synthetic strategies and structure–activity relationships
    Tathagata Pradhan, Ojasvi Gupta, Vivek Kumar, Sristi, Gita Chawla · 2022 · Archiv der Pharmazie
33. Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
    Olga González Albarrán, Cristóbal Morales, Manuel Pérez-Maraver, José Juan Aparicio-Sánchez, Rafael Simó · 2022 · Diabetes Therapy
34. Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis
    Dario Tuccinardi, Rita Zilich, Paola Ponzani, Nicoletta Musacchio, Valeria Manicardi, Alberto Rocca, Roberto Pontremoli, Paola Fioretto, Andrea Muscarà, Graziano Di Cianni et al. · 2025 · Cardiovascular Diabetology – Endocrinology Reports
35. Impact of point-of-care screening for hypertension, diabetes and progression of chronic kidney disease in rural Manitoba Indigenous communities
    Oksana Harasemiw, Thomas W. Ferguson, Barry Lavallee, Lorraine McLeod, Caroline Chartrand, Claudio Rigatto, Navdeep Tangri, Allison B. Dart, Paul V. J. Komenda · 2021 · Canadian Medical Association Journal
36. Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis
    Razan Al Namat, Letiţia Doina Duceac, Liliana Chelaru, Marius Gabriel Dabija, Cristian Guțu, Constantin Marcu, Maria Valentina Popa, Florina Popa, Elena Roxana Bogdan Goroftei, Elena Țarcă · 2023 · Diagnostics
37. Empagliflozin mitigates methotrexate-induced nephrotoxicity in male albino rats: insights on the crosstalk of AMPK/Nrf2 signaling pathway
    Amal Mishriki, Amira Karam Khalifa, Dina Anwar Ibrahim, Ghada Hashem, Laila Ahmed Rashed, Sahar Samir Abdelrahmen, Hesham Mahmoud · 2024 · Future Journal of Pharmaceutical Sciences
38. SGLT2 inhibitors use in kidney disease: what did we learn?
    Munaza Akunjee, Shikha Khosla, Eric Nylén, Sabyasachi Sen · 2025 · American Journal of Physiology-Endocrinology and Metabolism
39. Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
    Shun Kohsaka, Masayoshi TAKEDA, Johan Bodegård, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric T Wittbrodt, Peter Fenici · 2020 · Journal of Diabetes Investigation
40. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
    Nikola Lukic, Mirjana Mačvanin, Zoran M. Gluvic, Manfredi Rizzo, Djordje J. Radak, Jasjit S. Suri, Esma R. Isenović · 2023 · Current Medicinal Chemistry
41. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper
    Faiçal Jarraya, Abdou Niang, Hussein Bagha, Elliot Koranteng Tannor, Ernest Kiswaya Sumaili, Davy Ip Min Wan, Mogamat‐Yazied Chothia, Yewondwossen Tadesse Mengistu, François Folefack Kaze, Ifeoma Ulasi et al. · 2023 · Kidney International Reports
42. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies
    Pierre Delanaye, André Jacques Scheen · 2021 · Diabetes Epidemiology and Management
43. Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics
    Lilian Anagnostopoulou, Nikolaos Ktenopoulos, Anastasiοs Apostolos, Christos Fragoulis, Panayotis K. Vlachakis, Paschalis Karakasis, Μarios Sagris, Nikias Milaras, Maria I. Drakopoulou, Andreas G. Synetos et al. · 2026 · Diabetes/Metabolism Research and Reviews
44. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
    Lei Tian, Sinan Ai, Huijuan Zheng, Hanwen Yang, Mengqi Zhou, Jingyi Tang, Weijing Liu, Wenjing Zhao, Yaoxian Wang · 2022 · Frontiers in Pharmacology
45. Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis
    Min‐Hsiang Chuang, Yu‐Shuo Tang, Jui‐Yi Chen, Heng‐Chih Pan, Hung‐Wei Liao, Wen-Kai Chu, Chung‐Yi Cheng, Vin‐Cent Wu, Michael Heung · 2024 · Diabetes & Metabolism Journal
46. Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials
    Gailin Ye, Shuai Wang, Daoquan Peng · 2021 · Journal of Cardiovascular Pharmacology
47. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Yang Wang, Ning Xia · 2022 · Hormone and Metabolic Research
48. Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk
    Guntram Schernthaner, Per‐Henrik Groop, Philip A. Kalra, Claudio Ronco, Maarten W. Taal · 2020 · Diabetes Obesity and Metabolism
49. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
    Helena W. Rodbard, Andrea Giaccari, Bertrand Cariou, Satish K. Garg, Michael J Davies, Kiernan Seth, Sangeeta Sawhney · 2021 · Diabetes and Vascular Disease Research
50. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
    Maureen Wahinya, Zahid Ullah Khan · 2023 · Cureus
51. SGLT2 Inhibitors and Their Effect on Urolithiasis: Current Evidence and Future Directions
    Živka Dika, Marijana Živko, Marina Kljajić, Bojan Jelaković · 2024 · Journal of Clinical Medicine
52. Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials’ meta-analysis studies
    Pouria Khashayar, Farid Farahani Rad, Ozra Tabatabaei‐Malazy, Sara MohammadHosseinzadeh Golabchi, Patricia Khashayar, Mehdi Mohammadi, Sholeh Ebrahimpour, Bagher A. Larijani · 2024 · Diabetology & Metabolic Syndrome
53. Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and/or radiotherapy: a real-world data retrospective cohort study
    Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, Wen‐Jan Tuan, Roger J. Chammas · 2025 · BMC Cancer
54. Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats
    Xie Keyu, Ken Sugimoto, Minoru Tanaka, Hiroshi Akasaka, Taku Fujimoto, Toshimasa Takahashi, Yuri Onishi, Tomohiro Minami, Shino Yoshida, Yoichi Takami et al. · 2023 · Journal of Clinical Biochemistry and Nutrition
55. Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes
    Julita Tokarek, Emilian Budny, Maciej Saar, Kamila Stańczak, Ewa Wojtanowska, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2023 · Biomedicines
56. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)
    Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku · 2020 · Journal of Diabetes Investigation
57. Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: A systematic review and meta-analysis of randomized clinical trials
    Haiyan Cao, Youxia Liu, Zhixia Tian, Yuhang Lian, Junya Jia, Ming Rong Liu, Li Dong · 2021 · Diabetes Research and Clinical Practice
58. SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
    Antonio Raffaele Michele Granata, Francesco Pesce, Massimo Iacoviello, Massimiliano Anzaldi, Francesco Amico, Maria Rosaria Catalano, Giuseppe Leonardi, Carmela Gatta, Giusy Costanza, Salvatore Corrao et al. · 2022 · Frontiers in Nephrology
59. Softening the Stiff Heart
    Kim Alexander Connelly, Sean Cai · 2020 · JACC. Cardiovascular imaging
60. Cardiovascular Outcome of the SGLT2 Inhibitor in Acute Myocardial Infarction: A Meta-Analysis
    Siqi Hu, Ting Tang, Qingwen Yu, Xuhan Tong, Yao You, Shenghui Zhang, Chen Chen, Jiake Tang, Chunyi Wang, Hu Wang et al. · 2025 · Reviews in Cardiovascular Medicine
61. Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis
    Siqi Yang, Xi Zhao, Jing Zhang, Huan Liu, Yuhan Wang, Yao-Guang Wang · 2024 · Frontiers in Endocrinology
62. Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies
    Bojung Seo, Jialin Su, Yiqing Song · 2022 · European Journal of Clinical Pharmacology
63. Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis
    Yujia Li, Huilin Tang, Yi Maggie Guo, Hui Shao, Stephen E. Kimmel, Jiang Bian, Desmond Schatz, Jingchuan Serena Guo · 2024 · Frontiers in Pharmacology
64. Cardiorenal Benefits of SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Concomitant Hypertension
    Mi Wang, Li Zuo · 2025 · Cardiorenal Medicine
65. Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy
    Milind Y. Desai, Niccolò Maurizi, Elena Biagini, Philippe Charron, Fábio Fernandes, Esther González-López, Paul L. van Haelst, Kristina Hermann Haugaa, Christopher M. Kramer, Benjamin Meder et al. · 2025 · JACC Heart Failure
66. Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View
    Hiroyasu Bando · 2020
67. Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review
    Nikolaos Velidakis, Panagiotis Stachteas, Evangelia Gkougkoudi, Christodoulos E. Papadopoulos, Nikolaos P. E. Kadoglou · 2024 · Pharmaceuticals
68. SGLT2i as a First-line Antihyperglycemic in the Management of Type 2 Diabetes in the Context of Indians: A Systematic Review and Consensus
    Awadhesh Kumar Singh, Anoop Misra, Ashok Kumar Das, Anish Behl, Ankit Srivastava, Arunachalam Paneerselvam, Balaji Chidambaram, Banshi Saboo, Bipin Kumar Sethi, Brij Mohan Makkar et al. · 2023 · Journal of the Association of Physicians of India
69. Increasing Sodium-Glucose Cotransporter 2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway
    Laura Nishi, Cybele Ghossein, Anand Srivastava · 2022 · Kidney Medicine
70. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
    Ying Jie Chee, Rinkoo Dalan · 2024 · Biomedicines
71. Association of chronic kidney disease and cardiovascular disease risk with all-cause mortality: an interaction, joint and mediation analysis in Chinese adults
    Yang Li, Yiqin Shi, Bowen Zhu, Yafei Chen, Bo Shen, Shuan Zhao, Nana Song, Yi Fang, Xiaoqiang Ding · 2025 · BMC Public Health
72. Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus
    Debdipta Bose, Miteshkumar Rajaram Maurya, Mahanjit Konwar · 2023 · Indian Journal of Pharmacology
73. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
    Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, HARPREET SINGH BAJAJ, G.B. John Mancini, Norman C. Wong, April E Slee, Fernando G. Ang, Wally Rapattoni et al. · 2024 · Journal of the American Heart Association
74. Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection
    Francisco Epelde · 2024 · Medicina
75. Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
    Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang‐Liang Ding · 2020 · Endocrine
76. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
    Niti Mittal, Vikas Sehray, Rakesh Mittal, Surjit Singh · 2021 · European Journal of Pharmacology
77. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
    Ai‐Yu Yang, Hung‐Chun Chen · 2022 · Journal of Diabetes Research
78. Are gliflozins the new statins for diabetes?
    Dario Giugliano, Maria Ida Maiorino, Miriam Longo, Katherine Esposito · 2019 · Diabetes Research and Clinical Practice
79. Prediction of rapid kidney function decline using machine learning combining blood biomarkers and electronic health record data
    Girish N. Nadkarni, Fergus Fleming, James R. McCullough, Kinsuk Chauhan, Divya Anna Verghese, Cijiang He, John F Quackenbush, Joseph Vincent Bonventre, Barbara T. Murphy, Chirag R. Parikh et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
80. Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database
    Annamaria Mascolo, Alessia Zinzi, Mario Gaio, Donatella Ruggiero, Cristina Scavone, Francesco Rossi, Annalisa Capuano · 2024 · Pharmacological Reports
81. Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis
    Anna L. Kamdar, Robert Sykes, Andrew Morrow, Kenneth Mangion, Colin Berry · 2021 · Reviews in Cardiovascular Medicine
82. Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-Analysis
    Nicole Santos Felix, Mateus de Miranda Gauza, Larissa Teixeira, Maria Eduarda Schramm Guisso, Allêh Nogueira, Caroline Serafim Dagostin, Amanda Godoi, Sandro Augusto Goncalves Ribeiro, Juan C. Duque, José A. Moura-Neto et al. · 2024 · Korean Circulation Journal
83. Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
    Marlene Schwarzenbach, Flavia Elena Bernhard, Cecilia Czerlau, Daniel Sidler · 2021 · World Journal of Transplantation
84. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus
    Hong Zhang, Xiaoxue Zhu, Xiaojiao Li, Hong Chen, Min Wu, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Ying‐Jun Zhang, Yanhua Ding · 2019 · Diabetes Obesity and Metabolism
85. Impact of ChatGPT on Diabetes Mellitus Self-Management Among Patients in Saudi Arabia
    Turki M Alanzi, Wejdan M. Arif, Aldanah Alotaibi, Aasal Alnafisi, Raghad Alhwaimal, Nouf Altowairqi, Amal Alnifaie, Kadi Aldossari, Khulud Althumali, Nouf Alanzi · 2025 · Cureus
86. Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
    Kyriaki Vafeidou, Ourania Psoma, Georgios Dimakopoulos, Evangelos Apostolidis, Anastasia Sarvani, Eleni Gavriilaki, Michael N. Doumas, Vasilis Tsimihodimos, Kalliopi Kotsa, Theocharis Koufakis · 2025 · Pharmaceuticals
87. Noninsulin Therapies in Management of Type 1 Diabetes
    Zeb Ijaz Saeed, Jayachidambaram Ambalavanan, Melanie Natasha Rayan, Palak Patadia, Viral N. Shah · 2025 · Endocrine Practice
88. Clinical outcomes and safety of SGLT2 inhibitors in the older population with heart failure: A systematic review and meta-analysis
    Ayan Khalid, Rahul Balach, Anas Rasool, Shaikh Muhammad Daniyal, Muhammad Taha Nizami, Isbah Gul, Ashmat Naqvi, Gregg C. Fonarow, Saad Ahmed Waqas · 2026 · Archives of Gerontology and Geriatrics
89. Cardiovascular outcomes of SGLT-2 inhibitors’ subtypes in type 2 diabetes; an updated systematic review and meta-analysis of randomized controlled trials
    Pouya Ebrahimi, Hamidreza Soleimani, Mehrdad Mahalleh, Pegah Farisi, Maryam Taheri, Pedram Ramezani, Parnian Soltani, Roozbeh Nazari, Nahid Senobari, Seyedeh Maryam Mousavinezhad et al. · 2025 · Journal of Diabetes & Metabolic Disorders
90. Early prescription of SGLT2i for acute patient care: from current evidence to future directions
    Fabrizio Ricci, Silvio Saraullo, Andrea Boccatonda, Anna Sorella, Alessia Cipollone, Paola Simeone, Sabina Gallina, Francesca Santilli, Francesco Cipollone, Damiano D’Ardes · 2025 · Current Problems in Cardiology
91. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial
    Akihiko Koshino, Megumi Oshima, Clare Gabrielle Arnott, Robert A. Fletcher, George L. Bakris, Meg Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Carol A. Pollock, Hiddo J.L. Heerspink et al. · 2023 · Diabetes Obesity and Metabolism
92. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease
    Jeffrey Shi Kai Chan, Francesco Perone, Yasmin Bayatpoor, Gary Tse, Amer Harky · 2023 · Expert Opinion on Pharmacotherapy
93. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
    Tian‐Biao Zhou, Kaijin Yao, Yina Xie, Yongda Lin, Jiali Wang, Xiutian Chen · 2023 · Current Pharmaceutical Design
94. Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
    Soo Heon Kwak, Kyung Ah Han, Eun Sook Kim, Sung Hee Choi, Jong Chul Won, Jae Myung Yu, Seungjoon Oh, Hye Jin Yoo, Chong Hwa Kim, Kyung‐Soo Kim et al. · 2024 · Diabetes Obesity and Metabolism
95. Exploring the Pleiotropic Genes and Therapeutic Targets Associated with Heart Failure and Chronic Kidney Disease by Integrating metaCCA and SGLT2 Inhibitors’ Target Prediction
    Huanqiang Li, Ziling Mai, Sijia Yu, Bo Wang, Wenguang Lai, Guanzhong Chen, Chunyun Zhou, Jin Liu, Yongquan Yang, Shiqun Chen et al. · 2021 · BioMed Research International
96. Comparative efficacy and safety of sodium–glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
    Junhua Ma, Jiancan Lu, Peiling Shen, Xuemei Zhao, Hongling Zhu · 2023 · Renal Failure
97. Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
    Brian Tomlinson, Yanhong Li · 2023 · Expert Opinion on Pharmacotherapy
98. Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
    Saad Ur Rehman, Faiqa Rahman · 2020 · Cureus
99. Can SGLT-2 inhibitors improve cardiovascular outcomes and ensure safety for patients with type 2 diabetes and heart failure in Thailand? A real-world multicentre retrospective cohort study
    Tanawan Kongmalai, Amarit Tansawet, Oraluck Pattanaprateep, Cholatid Ratanatharathorn, Porntep Amornritvanich, Panu Looareesuwan, Burin Boonwatcharapai, Anon Khunakorncharatphong, Hataikarn Nimitphong, Varalak Srinonprasert et al. · 2024 · BMJ Open
100. Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
     Richard F. Hobbs, Richard J. McManus, Clare J Taylor, Nicholas Robert Jones, Joy K Rahman, Jane L. Wolstenholme, Louise Jones, Jennifer A. Hirst, Sam Mort, Ly‐Mee Yu · 2025 · Health Technology Assessment